CD69 and infection: Intranasal administration of a novel vaccine, based on recombinant adenoviral vectors (rAd) encoding influenza HA and nucleoprotein in combination with rAd-IL-1β promoted the generation of CD103+CD69+ TRM cells that mediated protection against infection with homologous and heterologous influenza virus strains (55).